Skip to content
10-Q

Quarterly Report

Seres Therapeutics, Inc. MCRB

0001193125-25-266011

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 9.05M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.77M sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.74M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 7.63M sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 7.5M sh
Capex Q3 2025 · Sep 30, 2025 $223K
Capex Q3 2025 · Sep 30, 2024 $290K
Operating Cash Flow Q3 2025 · Sep 30, 2025 $15.83M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$109.73M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $47.64M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $30.79M
Stockholders Equity Q3 2025 · Sep 30, 2025 $43.7M
Stockholders Equity Q3 2025 · Jun 30, 2025 $32.95M
Stockholders Equity Q3 2025 · Mar 31, 2025 $50.47M
Stockholders Equity Q3 2025 · Dec 31, 2024 $13.78M
Stockholders Equity Q3 2025 · Sep 30, 2024 $23.92M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$87.07M
Stockholders Equity Q3 2025 · Mar 31, 2024 −$59.74M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$44.86M
Current Liabilities Q3 2025 · Sep 30, 2025 $22.43M
Current Liabilities Q3 2025 · Dec 31, 2024 $41.22M
Total Liabilities Q3 2025 · Sep 30, 2025 $99.78M
Total Liabilities Q3 2025 · Dec 31, 2024 $126.03M
Current Assets Q3 2025 · Sep 30, 2025 $51.53M
Current Assets Q3 2025 · Dec 31, 2024 $38.67M
Total Assets Q3 2025 · Sep 30, 2025 $143.47M
Total Assets Q3 2025 · Dec 31, 2024 $139.81M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.94
Eps Diluted Q3 2025 · Sep 30, 2025 $2.40
Eps Diluted restated Q3 2025 · Sep 30, 2024 $11.63
Eps Diluted restated Q3 2025 · Sep 30, 2024 $2.10
Eps Basic Q3 2025 · Sep 30, 2025 $0.94
Eps Basic Q3 2025 · Sep 30, 2025 $2.41
Eps Basic restated Q3 2025 · Sep 30, 2024 $11.63
Eps Basic restated Q3 2025 · Sep 30, 2024 $2.10
Sga Expense Q3 2025 · Sep 30, 2025 $9.48M
Sga Expense Q3 2025 · Sep 30, 2025 $31.62M
Sga Expense Q3 2025 · Sep 30, 2024 $12.71M
Sga Expense Q3 2025 · Sep 30, 2024 $40.72M
Rd Expense Q3 2025 · Sep 30, 2025 $12.62M
Rd Expense Q3 2025 · Sep 30, 2025 $37.38M
Rd Expense Q3 2025 · Sep 30, 2024 $16.46M
Rd Expense Q3 2025 · Sep 30, 2024 $51.76M
Net Income Q3 2025 · Sep 30, 2025 $8.2M
Net Income Q3 2025 · Sep 30, 2025 $21.03M
Net Income Q3 2025 · Jun 30, 2025 −$19.86M
Net Income Q3 2025 · Mar 31, 2025 $32.68M
Net Income Q3 2025 · Sep 30, 2024 $88.78M
Net Income Q3 2025 · Sep 30, 2024 $15.77M
Net Income Q3 2025 · Jun 30, 2024 −$32.87M
Net Income Q3 2025 · Mar 31, 2024 −$40.13M
Operating Income Q3 2025 · Sep 30, 2025 −$22.48M
Operating Income Q3 2025 · Sep 30, 2025 −$74.59M
Operating Income Q3 2025 · Sep 30, 2024 −$29.17M
Operating Income Q3 2025 · Sep 30, 2024 −$92.48M
Revenue Q3 2025 · Sep 30, 2025 $351K